INVIVYD, INC. Assets, Fair Value Adjustment
INVIVYD, INC. (IVVD) reported Assets, Fair Value Adjustment of $83.06 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes
us-gaap:AssetsFairValueAdjustment · last filed 2024-03-28
- INVIVYD, INC. assets, fair value adjustment for the quarter ending 2023-09-30 was -$93.42M.
- INVIVYD, INC. assets, fair value adjustment for the quarter ending 2023-06-30 was -$30.47M.
- INVIVYD, INC. assets, fair value adjustment for the quarter ending 2023-03-31 was $206.96M.
- INVIVYD, INC. assets, fair value adjustment for the quarter ending 2022-12-31 was $139.40M.
- INVIVYD, INC. assets, fair value adjustment for fiscal 2022 was $279.92M.
| Period end | Assets, Fair Value Adjustment 3 month | Assets, Fair Value Adjustment 6 month | Assets, Fair Value Adjustment 9 month | Assets, Fair Value Adjustment 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$93.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$123.89M derived: sum of 2 quarters · filed 2023-11-09 | $83.06M 10-Q · filed 2023-11-09 | $222.46M derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | -$30.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $176.48M 10-Q · filed 2023-08-10 | $315.88M derived: sum of 3 quarters · filed 2024-03-28 | |
| 2023-03-31 | $206.96M 10-Q · filed 2023-05-11 | $346.35M derived: sum of 2 quarters · filed 2024-03-28 | ||
| 2022-12-31 | $139.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $279.92M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | $140.52M 10-Q · filed 2022-11-10 | |||
| 2021-09-30 | $188.05M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |